Dianthus Therapeutics (DNTH) Proxy filing summary

Executive summary

• Annual meeting scheduled for May 21, 2026, to be held virtually for stockholders of record as of March 30, 2026.

• Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report on Form 10-K, are available online or by request.

Voting matters and shareholder proposals

• Election of three Class II director nominees to serve until the 2029 annual meeting or until successors are qualified.

• Advisory vote to approve compensation paid to named executive officers.

• Ratification of Deloitte & Touche, LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

Board of directors and corporate governance

• Board recommends voting for all director nominees and for both other proposals.

• Director nominees are Sujay Kango, Anne McGeorge, and Jonathan Violin, Ph.D.